Work

A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.3043

Authors: Fatima H Karzai, Andrea Borghese Apolo, David Adelberg, Ravi A. Madan, James L. Gulley, Philip M. Arlen, Howard L. Parnes, Ann Pierpoint, David R. Kohler, Jane B. Trepel, Douglas K. Price, Seth M. Steinberg, William Douglas Figg, William L. Dahut

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589973308

Cites:

Cited by: 8

Related to: 10